Diamedix Diagnostics

Based in Romania, Diamedix Diagnostics specializes in diagnostic testing solutions, particularly for respiratory infections. Their innovative products provide rapid results, supporting healthcare providers in clinical decision-making during critical situations. Diamedix Diagnostics, founded in 1996 in Bucharest, Romania, focuses on diagnostic testing solutions. The company has not undergone any significant pivots but was recently acquired by Emma Capital in March 2025 from Buenavista Equity Partners for undisclosed financial terms.

The founder's history and previous ventures are not publicly detailed. To date, Diamedix Diagnostics has raised a total of EUR 12. 000 mn across 2 funding deals, with the latest being a Buyout round amounting to EUR 12. 000 mn.

Diamedix Diagnostics specializes in the provision of diagnostic testing solutions tailored for respiratory infections, including COVID-19 and influenza A/B. Their key products include the CLINITEST® Rapid COVID-19 + Flu A/B Antigen Test for quick differential diagnosis, real-time PCR multiplex tests for identifying respiratory viruses, and ELISA kits for detecting COVID-19 antibodies. These solutions target healthcare providers across hospitals, laboratories, and clinics, serving both public and private sectors in the European Union and potentially expanding to other international markets. In the most recent financial year, Diamedix Diagnostics reported a revenue of EUR 11,488,000 with an EBITDA of EUR 2,872,000.

Following its acquisition by Emma Capital in March 2025, Diamedix Diagnostics aims to enhance its medical and diagnostic services and strengthen its market presence. The company is expected to focus on developing new testing products and expanding its reach into new geographical markets. The recent funding will support these initiatives as Diamedix seeks to solidify its position in the healthcare market.